Stockscreener 앱 받기
1.74
1.75%
0.03
시간 외 거래:
1.72
-0.02
-1.15%
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd Q4 Earnings Call Highlights - Yahoo Finance
Invivyd earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com South Africa
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com South Africa
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com
Invivyd appoints Michael Mina as chief medical officer - Investing.com India
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Manila Times
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
New study maps COVID protection to antibody levels, not variants - Stock Titan
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd CSO Allen sells shares worth $58,600 - Investing.com India
Invivyd CSO Allen sells shares worth $58,600 By Investing.com - Investing.com Nigeria
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com Australia
Invivyd (NASDAQ: IVVD) legal chief sells shares in tax sell-to-cover plan - Stock Titan
Invivyd (IVVD) HR chief logs RSU vesting and tax sell-to-cover sales - Stock Titan
Timothy Edward Lee Sells 19,663 Shares of Invivyd (NASDAQ:IVVD) Stock - MarketBeat
RA Capital discloses 9.99% Invivyd (IVVD) stake via shares and warrants - Stock Titan
BVF group discloses 9% Invivyd (IVVD) stake via shares and warrants - Stock Titan
Invivyd’s COVID antibody VYD2311 receives FDA fast track - MSN
Point72 discloses 6% Invivyd (IVVD) ownership in Schedule 13G/A - Stock Titan
Can Invivyd Inc. navigate macro headwindsMarket Performance Recap & Safe Capital Investment Plans - mfd.ru
Does Invivyd Inc. have a sustainable dividendEarnings Overview Summary & Safe Capital Preservation Plans - mfd.ru
What makes Invivyd Inc. stock attractive to growth funds2025 Retail Activity & Daily Profit Maximizing Trade Tips - mfd.ru
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Invivyd prices $125M stock offering at $2.50 per share - MSN
Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial By Investing.com - Investing.com South Africa
3.69%
0.68%
자본화:
|
볼륨(24시간):